Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy

Shanghai Pulmonary Hospital, Shanghai, China500 enrolled

Overview

The aim of this study is to explore the application of surface-enhanced Raman scattering (SERS) technology and specific PD-L1 detection fluorescent probes in the clinical diagnosis and prognosis of lung cancer immunotherapy, and further promote the rapid diagnosis of lung cancer and the precision of tumor immunotherapy.

The aim of this study is to explore the application of surface-enhanced Raman scattering (SERS) system in the diagnosis of benign and malignant lung cancer biopsy, and to promote the rapid diagnosis of lung cancer. In addition, the correlation between tumor PH value, PD-L1 expression detected by fluorescent probes and the efficacy and prognosis of immunotherapy was explored. Based on this, the immunotherapy efficacy and prognosis prediction models based on patients' clinical information, PD-L1 expression by immunohistochemistry, PD-L1 expression by fluorescent probes and PH value detected by SERS were constructed to promote the precision of tumor immunotherapy.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 19 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Voluntary participation in clinical research; Fully understand and informed the study and sign the informed consent form (ICF); Be willing to follow and be able to complete all trial procedures. 2. Male or female aged 18-75 years or more when signing ICF. 3. Fiberoptic bronchoscopy or percutaneous lung biopsy was performed. 4. Lung cancer cannot be surgically resected. 5. At least one measurable target lesion assessed by IRRC according to RECIST 1.1. Patients must provide eligible tumor tissue for PD-L1 expression and PH measurement. (7) Related laboratory tests suggested that chemotherapy and immunotherapy could be tolerated. Exclusion Criteria: 1. NSCLC patients with unclear diagnosis; 2. Patients with contraindications to chemotherapy or immunotherapy. 3. Contraindication of lung biopsy. 4. Other active malignant tumors within the past year or at the same time. 5. The patient had a known history of psychotropic drug abuse or drug use; She had a history of alcohol abuse. 6. According to the investigator's judgment, the patient had other factors that may lead to early termination of the study.

Outcomes

Primary Outcomes

Time from randomization to death (from any cause).

Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 24 months

PFS

The time between the initiation of randomization and the occurrence (any aspect) of tumor progression or death (from any cause).

Time frame: From date of diagnosis until the date of first documented progression from any cause, whichever came first, assessed up to 24 months

ORR

Refers to the proportion of subjects whose tumors shrink by a certain amount and remain for a certain period of time, including those with CR+PR.

Time frame: The proportion of patients who achieved a 30%(usual) reduction in tumor volume while maintaining the minimum required duration was calculated at month 24 of the study

DOR

Is the time from the first documented response (CR or PR) to the first documented disease progression or death, whichever occurs first.

Time frame: The time from first diagnosis of CR or PR to diagnosis of PD was calculated at 24 months of study.

Central Contacts

Yayi He, PHD,MD

CONTACT

+86 021-65115006 doctorjael@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.